Organic Active Ingredients TRIZ Cases

Controlled anti-solvent crystallization creates a stable TETA.4HCl Form B that resists humidity and room-temperature degradation.

Milder bases and protected intermediates cut racemization and isomer impurities while improving N/O-alkylation selectivity and yield.

Bifunctional IRAK4 degraders recruit E3 ligases to drive ubiquitination and proteasomal removal, lowering IRAK4 with low toxicity.

Blocking IL-6 or IL-6R offers a targeted option for severe refractory asthma, reducing exacerbations and steroid dependence.

Modified mRNA plus microRNA mimics reprogram primary human fibroblasts into iPSCs without feeder cells or genomic integration.

Demethylating STING-deficient melanoma cells before STING agonist treatment boosts chemokine-driven T cell recruitment and TIL function.

By raising intracellular cAMP, PDE1 inhibition drives apoptosis and limits immune-cell recruitment, helping control colorectal cancer metastasis.

Autologous CD19 CAR-T cells paired with lymphodepleting chemotherapy improve refractory MCL and B-cell ALL treatment while managing CRS.

Controlled polymorphs and solvates make this benzofuran carboxamide more stable, non-hygroscopic, and suitable for consistent drug formulation.

Acellular amniotic fluid treats ischemic injury without invasive procedures, reducing infarct size, preserving cardiac function, and limiting fibrosis.

Alcohol-substituted imidazo[1,2-a]pyridines balance potent NMT inhibition with better cell permeability and metabolic stability for cancer therapy.

New ISR modulator compounds tune substituents to stabilize eIF2B, lower phosphorylated eIF2alpha, and improve solubility and selectivity.

Indoline derivatives act upstream to reduce oxidative stress and pro-inflammatory cytokine release while limiting adverse effects in chronic disorders.

A two-component PEG hydrogel sealant improves lung tissue compliance, adhesion, and visibility while setting quickly on a deflated lung.

A 5'-CP gapmer with modified wing regions preserves RPS25 silencing while reducing delayed central toxicity and supporting RNase-driven RNA degradation.

Alginate oligomers bind calcium to reduce dense clot formation, increase clot permeability, and improve anticoagulation response.

An oil-in-water emulsion uses amphoteric surfactant and alkoxylated cetyl alcohol to improve sodium cromoglicate skin delivery with low irritation.

Biotin functionalization boosts polymer uptake in pathogens and cancer cells while coacervate delivery reduces mammalian-cell toxicity.

A SIRPα-linked BRCA siRNA complex targets CD47-positive cancer cells to improve siRNA delivery and boost PARP inhibitor response in wild-type BRCA tumors.

Charge-neutralizing backbone moieties improve oligonucleotide uptake and membrane penetration while preserving stability for therapeutic use.

A crystalline fine-particle PRX-3140 potassium salt improves dissolution, stability, and absorption consistency for oral delivery.

Dry powder active agent placed on the adhesive contact surface improves transfer to the substrate while preserving bond strength and stability.

Using SP6 RNA polymerase, this case shows large-scale full-length mRNA production with low dsRNA contamination and no chromatography step.

Controlling liposomes to 90-110 nm with low polydispersity extends blood retention and sustains CD1d ligand levels for transplant therapy.

Local Wnt5a inhibition targets Schlemm's canal to lower intraocular pressure while avoiding the side effects and scarring of standard glaucoma treatments.

A stepwise acetylation-oxidation-demethylation route produces morin above 95% purity without kaempferol and avoids yellowwood extraction.

Reduced-frequency tralokinumab dosing maintains atopic dermatitis control while lowering injection burden, drug exposure, and steroid dependence.

A heat-treated ergothioneine derivative removes hydrogen peroxide and reduces related cytotoxicity across varied composition uses.

A ribose-based GalNAc monomer improves ASGPR-mediated liver delivery of oligonucleotides and strengthens AGT gene expression inhibition.

A piston-driven earplug chamber injects fluid into the ear canal while sealing against leakage and providing acoustic isolation.

Epigenetic inhibitors modulate EGFR amplification to reduce tumor heterogeneity and restore sensitivity to EGFR-targeted cancer drugs.

By regulating RNA m6A methylation, this indole compound targets hyperkeratosis at the cause and helps reduce stratum corneum thickness.

An LNP-delivered self-amplifying IL-12 replicon drives immunogenic cell death at the tumor site while extending immunity to distal tumors.

Local delivery of a formula (I) antibacterial targets Gram-positive diabetic foot infection, reducing biofilm and systemic side effects.

Controlled particle size, metal-free excipients, and wet granulation improve eltrombopag olamine tablet stability and dissolution.

Spirocyclic compounds lower EPO levels with strong chemical stability, offering a targeted option for renal cell carcinoma and polycythemia.

Sequence-specific zinc-finger arrays paired with a nuclease domain improve RHO locus cleavage specificity and editing efficiency for retinitis pigmentosa.

Roluperidone helps prevent schizophrenia relapse by stabilizing negative symptoms without dopamine-related Parkinsonism or sedation.

Mechanochemical mixing, extrusion, and continuous extraction improve nicotinoyl riboside yield, scale-up, and crystalline stability.

Berberine compositions target nicotinic acetylcholine receptors to curb dopamine release, reducing nicotine dependency with fewer side effects.

Biodegradable particles combine surface immune signals with encapsulated cytokines to expand Tregs and treat autoimmunity without broad immunosuppression.

Defined NK-1 antagonist crystal forms and solvates improve reproducibility, stability, solubility, and bioavailability for formulation.

Modified indole serotonin agonists aim to preserve rapid CNS therapeutic effects while reducing tolerance and adverse reactions.

Targeting Hedgehog-activated myofibroblasts with taladegib helps reduce fibrosis and improve lung function in progressive pulmonary fibrosis.

Combining anti-coagulants with B-Raf or MEK inhibitors helps curb OPN-associated melanoma growth and metastasis by modulating the tumor microenvironment.

A surfactant-based oral testosterone undecanoate formulation treats deficiency while maintaining blood pressure control and lowering cardiovascular risk.

Membrane-fusing liposome-coated porous silicon nanoparticles deliver genetic and other anionic cargo directly to cells while avoiding lysosomal degradation.

Metal salt forms of a tetrahydroisoquinoline AT2R antagonist improve water solubility and pharmacokinetics for neuropathic pain therapy.

Remodeled N297 glycan improves internalization of a CLDN6/CLDN9-targeting antibody-PBD conjugate, boosting tumor cell cytotoxicity.

Small-molecule NF-κB inhibitors selectively curb excessive inflammation while preserving needed immune response in autoimmune and cancer treatment.

Crystalline maleate salt forms improve water solubility and stability of a 3-cyanoquinoline cancer drug, boosting absorption over the free base.

Small molecules preferentially bind MTA-bound PRMT5 in MTAP-null tumors, improving efficacy while limiting toxicity in normal tissues.

Selective GABA A γ1 PAMs enhance inhibitory signaling for ASD-related symptoms while avoiding sedation linked to non-selective benzodiazepines.

A BMPR1B inhibitor in induction medium improves the efficiency and stability of directing pluripotent stem cells into neural lineage cells.

Targeting IL-17A with secukinumab offers faster rheumatoid arthritis symptom control in high-risk patients while avoiding broad DMARD toxicity.

Clinical use of vafidemstat targets core ASD symptoms and reduces aggression without the sedation or weight gain seen in current therapies.

Pre-capped oligonucleotide primers enable one-step synthesis of homogeneous Cap 0-2 RNAs with higher yield, lower cost, and reduced immunogenicity.

Liposomal mitoxantrone improves advanced breast cancer treatment by preserving efficacy while reducing cardiotoxicity and adverse effects.

Stable crystal and salt forms of a dual FLT3/IRAK4 inhibitor improve AML treatment by addressing resistance while maintaining strong physical stability.

Gut microbiota modulation with 2'-FL, 6'SL, and LNT raises kynurenic acid to reduce infant abdominal pain, crying, and sleep disruption.

Targeting ITPRIPL1 binding to CD3ε and NRP2 enables immune-response modulation and tumor suppression across multiple disease settings.

Specific salt, temperature, and loading time conditions raise EV payload association while reducing dissociation and improving delivery stability.

Formula I compounds improve plasma kallikrein inhibition specificity and therapeutic effect across hereditary angioedema and retinal edema disorders.

A natural flavonoid suppresses IL-17A and the IL-23/STAT3 pathway to reduce inflammation with fewer side effects.

A pressurized wound irrigation stream delivers chlorhexidine and octenidine together to cut irrigation time and lower microbial burden.

New quinazoline crystal forms improve blood-brain barrier penetration and ErbB2 selectivity for treating breast cancer brain metastases.

High-nicotine formulations use organic acids to limit evaporation and substrate spreading while keeping aerosol delivery stable and precise.

By recruiting LRRK2 to an E3 ubiquitin ligase, these PROTAC compounds overcome kinase inhibitor resistance through targeted degradation.

A steroid GABAA regulator crystal form enables once-daily oral dosing with antidepressant effects within 24 hours and sustained relief.

Combining NMN with mogroside V improves blood glucose control, protects islet cells, and inhibits fat accumulation at lower cost.

Stable solvent-free crystal forms reduce moisture uptake and improve processing of acetylcholinesterase inhibitors for neurodegenerative drugs.

Using Semaphorin 3B as a focused marker streamlines membranous nephropathy diagnosis and speeds immunosuppressive treatment decisions.

Novel nitrogen-containing bicyclic compounds inhibit IRAK-4 while reducing off-target effects and genetic toxicity in autoimmune therapy.

Novel tricyclic heterocycles improve KRas G12C inhibition while supporting oral delivery, better pharmacokinetics, and fewer adverse effects.

Modified KNG siRNA with a liver-targeting conjugate improves stability and specificity for septicemia treatment while limiting off-target effects.

Alkyne-containing phenylethynyl-thiophene compounds lower caspase 3, reduce apoptosis, and support oral treatment of degenerative disorders.

Deuterated domperidone with tailored excipients improves bioavailability while lowering Cmax and AUC to reduce QT prolongation risk.

CRISPR knockout of PDCD1 helps allogeneic CAR-T cells reduce immunogenicity and reactivity while improving activity, retention, and expansion.

Multiple tertiary amino groups help phosphatidylamine LNPs improve transfection stability and tissue-targeted nucleic acid delivery.

An emulsified L-leucine and fish oil composition uses polysorbate, gum, and aromas to mask fishy taste while improving formulation stability.

A transitional B. longum strain paired with HMOs helps stabilize infant gut microbiota, modulate cytokines, and lower infection risk.

Targeting HMBOX1 with RNA interference helps suppress ubiquitin ligases and slow muscle weight loss and fiber shrinkage.

A half-life-matched oral GLP-1 dosing regimen reduces plasma variability, limits nausea and vomiting, and improves efficacy.

A potent ABHD6 inhibitor is tuned for low P-glycoprotein excretion, enabling CNS migration while minimizing central side effects.

A dispersible Form IV benzamide composition improves swallowability for pediatric or dysphagic patients while preventing polymorphic interconversion.

Modified oligonucleotides promote SMN2 exon 7 inclusion to raise full-length SMN protein and improve key SMA symptoms.

Modified phosphate groups with triazine improve oligonucleotide cell penetration, stability, and target binding while staying compatible with standard synthesis.

By binding both the ATP site and αD site, these CK2α inhibitors improve kinase selectivity while maintaining potent enzyme inhibition.

A ribose-based GalNAc monomer improves ASGPR-mediated liver delivery of oligonucleotides while strengthening AGT gene inhibition.

A core-shell LPNP design uses electrostatic binding and hydrophobic anchoring to simplify mRNA delivery while improving stability and transfection.

Ionizable APD-capped cationic peptoids improve nucleic acid uptake and endosomal escape while limiting toxicity and immune response.

Combining omega-3 fatty acid salts with Boswellia extracts boosts SPM formation and improves bioavailability for inflammatory conditions.

By activating intestinal uric acid transporters with minimal systemic absorption, this case lowers blood uric acid while reducing liver and kidney burden.

A stepwise intermediate route uses specific reducing agents and activators to raise oligonucleotide analogue purity and yield at lower cost.

Targeting Cys528 in XPO-1, these triazolyl compounds block cargo protein export and help retain tumor suppressor proteins for tumor treatment.

Low-buffer VVN001 eye drops balance pH and osmolarity to block LFA-1/ICAM-1, improving comfort, residence time, and bioavailability.

Adding TPGS surfactant to a solid pyrazole composition improves solubility, oral bioavailability, and atopic dermatitis efficacy.

A two-stage extraction with resin adsorption combines avenanthramides and β-glucans in a controlled ratio while keeping salt low.

Separator segments and localized nucleoside modifications help HBV antisense oligonucleotides cut HBsAg and HBeAg while reducing liver toxicity.

Novel VMAT2 inhibitor compounds extend half-life and brain exposure to treat tardive dyskinesia with fewer doses and reduced adverse reactions.

Reduced nitrosomorpholine levels and a stable esreboxetine tablet blend help improve fibromyalgia treatment consistency while limiting tolerability issues.

Hydrolysable polymer-TTX conjugates enable tunable long-lasting nerve blockade while reducing local and systemic toxicity.

Using gossypetin to inhibit protein aggregation, this case targets Alzheimer's progression while improving memory and cognitive function.

Hetero-bifunctional compounds recruit LRRK2 to cereblon for ubiquitination and degradation, helping address Parkinson's-related pathology.

Multiple crystalline forms of a JAK2 inhibitor improve solubility and therapeutic effect while balancing formulation and manufacturing complexity.

Novel aza-benzothiophene and aza-benzofuran compounds target heartworms and other endoparasites, including macrocyclic lactone-resistant strains.

Controlled sulfation and salification turn terrestrial chondroitin sulfate into metal salts with stronger anti-inflammatory, bone-protecting, and cartilage-protecting effects.

Selective oral factor D inhibitor compounds curb aberrant complement activation to reduce harmful inflammation across immune, renal, and ocular disorders.

A hydrophobic buccal testosterone composition uses humectants, oil, and surfactants to bypass first-pass metabolism and sustain levels for 12-24 hours.

Localized sinus scaffolds release mometasone for over 12 weeks to maintain patency, reduce inflammation, and avoid repeat surgery.

Novel oxopyrrolidine urea compounds activate FPR2 to resolve inflammation, stabilize plaques, and support myocardial healing.

Continuous API impregnation into porous carriers improves blend uniformity, limits agglomeration, and supports scalable oral drug manufacturing.

A banded nested capsule keeps incompatible fill materials separate and uses apertures to enable timed or simultaneous release in digestive fluids.

New pyridoindole ER modulators achieve complete antagonism while enabling oral dosing, addressing resistance and injection-only limits.

A pyrimidine compound linked to squalene via a spacer boosts TLR7/8-driven immune activation, improving subunit vaccine adjuvant potency.

Halophthalimides target TNF-α, inflammation, and iNOS in one compound class, with added antiviral activity against SARS-CoV-2.

Localized spironolactone delivery treats excess androgen skin symptoms while reducing systemic side effects such as diuresis and nausea.

A stable PARP inhibitor crystal form improves batch consistency, resists heat, humidity, and light, and helps reduce toxic side effects.

A genomic tumor heterogeneity score turns variant and driver mutation data into a biomarker for treatment choice and response monitoring.

A defined crystalline form with hydrophilic polymers improves dissolution and oral bioavailability without sacrificing storage stability.

Enteric-coated spray-dried particles protect active ingredients from stomach acids, improving oral bioavailability consistency and faster bloodstream uptake.

Novel zwitterion and potassium salt solid forms smooth plasma exposure of a catecholamine prodrug to reduce peaks, side effects, and off fluctuations.

A TRβ agonist is paired with primary cancer therapy to redifferentiate resistant thyroid and breast cancer cells and restore treatment sensitivity.

Tricyclic TLR7/TLR8 agonists improve solubility, stability, and safety while supporting durable antitumor activity in antibody conjugates.

Chiral oxazepane carboxamides inhibit DPP1 and related proteases while reducing elastin-rich tissue binding in asthma and COPD.

Amorphous lumateperone stabilized with excipients enables faster oral onset while preserving formulation stability and combination flexibility.

A stable Form I crystal reduces heat and moisture degradation of a pyrazolopyrimidine ester BTK prodrug while enabling simple storage.

A stable liquid ActRIIA-Fc formulation uses excipients to limit aggregation at high concentration while targeting vascular remodeling in PH.

A GDC-6036 and inavolisib regimen targets KRasG12C-positive tumors while avoiding PI3KCA pretesting and reducing treatment delay.

A dose-tuned levonorgestrel regimen improves ovulation inhibition while limiting irregular bleeding and hypoestrogenic side effects.

APL targets early NASH pathology by reducing liver inflammation, ballooning, fibrosis, and steatosis before transplant-stage cirrhosis.

Systematic FXR agonist structure changes improve receptor modulation while balancing therapeutic efficacy and safety profile.

Selective targeting of IL1R2, PD-1 ligands, and CCR8 enables ADCC depletion of tumor Treg cells while limiting autoimmunity.

A segmented vaginal ring places high-solubility and low-solubility drug sections in sequence to curb initial burst and enable ambient storage.

Reversible covalent DPP1 inhibitors curb neutrophil elastase-driven tissue damage while helping preserve normal DPP1 physiological function.

ApoE-bearing rHDL nanoparticles cross the BBB and trigger cholesterol efflux to kill glioblastoma and pancreatic cancer cells.

Substituted tetrahydropyrrolo-pyridinone compounds modulate muscarinic receptors to improve treatment of refractory depressive, bipolar, and schizophrenia disorders.

Early GABA intervention aims to slow cognitive decline and improve memory, attention, and mental health in at-risk elderly subjects.

Targeting F2R, SARM1, RyR, RhoA, ROCK, LPAR1, and mTORC1 helps block cilia disassembly and restore function in ciliopathies.

Novel pyrido-pyrazole compounds improve DDR1 and DDR2 inhibition to better regulate collagen-driven fibrosis and cancer pathways.

Formula I compounds modulate LRRK2 kinase activity to address inadequate treatment options for neurodegenerative, CNS, and inflammatory diseases.

Branched-tail ionizable lipids in LNPs improve RNA delivery to mammalian cells while lowering immunogenicity and boosting therapeutic index.

Combining glycine, NAC, and nicotinamide riboside helps restore glutathione, reduce oxidative stress, and support mitochondrial function.

iPSC-derived platelets carry protein therapeutics with higher loading and natural tissue targeting, avoiding donor variability and nanoparticle immune limits.

Using cyclosporine dissolved in 1-perfluorobutyl-pentane, this case shows lower-dose dry eye treatment with fewer ocular adverse effects.

Before-bed tasimelteon regulates REM sleep to improve RBD symptoms while avoiding benzodiazepine side effects and melatonin variability.

Selective BTK inhibition addresses chronic spontaneous urticaria that resists antihistamines or omalizumab, reducing wheals and itch.

A multilayer absorbent underwear structure delivers cannabidiol through skin contact while controlling moisture, leakage, odor, and menstrual discomfort.

Using endogenous Lac-Phe, this case shows a way to improve ischemic heart function by promoting angiogenesis and limiting inflammation.

An MYH11 agonist drives pluripotent stem cells toward stable contractile smooth muscle cells to inhibit intimal hyperplasia and lower restenosis risk.

Modified exatecan derivatives improve Topo I inhibition, membrane permeability, and physicochemical stability for cancer treatment.

Small molecules bind the MASP-2 serine protease domain to block the lectin pathway while preserving classical complement activity.

Targets P2X4 receptors to treat inflammatory respiratory disease, improving airflow and cough symptoms with fewer side effects.

PepT1-mediated troriluzole delivery improves bioavailability and exposure predictability while reducing liver burden in glioblastoma treatment.

Substituted quinazoline diamines selectively inhibit SMARCA2 to suppress growth and induce apoptosis in SMARCA4-deficient tumors.

Chemically modified siRNA and chimeric RNAi combinations inhibit IRF4 and c-Myc to curb refractory multiple myeloma with lower toxicity.

Using hypericin in higher molar amounts with remdesivir or sofosbuvir improves antiviral efficacy while reducing toxicity and side effects.

Intermittent dosing of tight-binding RAS(ON) inhibitors preserves tumor inhibition while reducing wild-type RAS toxicity in normal tissues.

Controlled bupropion coadministration slows dextromethorphan metabolism, raises plasma exposure, lowers dextrorphan, and reduces adverse events.

Blocking CGRP with intravenous antibodies relieves migraine within hours and also helps prevent recurrent headache episodes.

Protein kinase degraders lower HPK1, MEK1/2, FLT3, and Aurora levels to address resistance, side effects, and limited efficacy in cancer treatment.

A PVA-sodium hyaluronate microneedle patch improves corneal penetration and ocular retention to treat severe corneal wounds.

Defined bacterial and fungal combinations use sequence and metabolic signatures to reduce inflammatory biomarkers in aging-related immune disorders.

Pyridazinone compounds target the MAX-MYC interface to suppress MYC activity and reduce tumor growth, viability, and metastasis.

Novel substituted benzene compounds inhibit NLRP3 inflammasome activation while improving pharmacokinetics and central transferability.

New lifitegrast crystal forms improve solubility, heat and moisture stability, and formulation bioavailability for pharmaceutical compositions.

A liposomal blend of DMH, NAC, prickly pear, and electrolytes improves hydration, absorption, and protection against alcohol-related effects.

RFID-based lifecycle tracking records cannabis cultivation, harvest, and packaging events to prevent diversion and support quality oversight.

A 5-25% topical spironolactone formulation targets androgen- and stress-related skin conditions while reducing systemic adverse effects.

Staged subcutaneous CD20/CD3 bispecific dosing spreads treatment across cycles to curb cytokine toxicity and tumor lysis while preserving efficacy.

By removing phosphatidylcholine and minimizing PEG, these LNP compositions reduce accelerated blood clearance and repeat-dose toxicity.

Ester treprostinil prodrugs extend delivery, reduce site pain, and improve oral bioavailability by limiting first-pass loss.

A selective non-peptide MC2R antagonist lowers ACTH-driven cortisol and androgen levels while avoiding mineralocorticoid disruption.

Protein-wall SAMe microcapsules reduce hygroscopicity while improving stability, GI compatibility, and direct tablet compression.

A small-molecule bridge directs E2 anti-fluorescein CAR T cells to cancer cells, reducing off-target toxicity and controllable activation.

Specific CBG:THC ratios create cannabinoid compositions that lower THC-induced anxiety while maintaining a more relaxed, predictable effect.

A personalized neoantigen RNA vaccine combined with PD-1 blockade and chemotherapy helps overcome PDAC immunosuppression and boost T-cell responses.

A pre-trauma BCAA and vitamin composition helps blunt glutamate excitotoxicity and reduce traumatic brain injury sequelae.

Small-molecule benzoannulene SERDs degrade ERα to address mutation-driven resistance in endocrine treatment of breast cancer.

LNP-delivered TnpB mRNA and recombinant ncRNA improve in vivo gene editing precision, efficiency, and delivery scalability.

Controlled crystallization creates solid-state FAP inhibitor forms with properties better suited to drug manufacturing, formulation, and bioavailability.

PLGA nanoparticles in a thermoreversible nanogel sustain ocular sunitinib delivery, reducing dosing frequency and improving AMD anti-angiogenesis.

Herbal stabilizers encapsulated in hydroxypropyl-β-cyclodextrin help low-dose actives stay stable while reducing bilirubin loss.

Combining natural pigments with light boosts mitochondrial electron transfer to raise ATP production while lowering ROS and oxidative stress.

Tricyclic compounds tune GSK3 selectivity, brain penetration, and metabolic stability to reduce off-target kinase effects in CNS-related therapy.

Timed 3-MMC dosing targets PMS and PMDD symptoms while avoiding the cost and side-effect burden of conventional drugs.

Linked benzazepine conjugates target CCK2R and splice variants to improve tumor imaging, internalization, and selective cancer therapy.

An intermediate LNG or NG daily dose improves contraceptive efficacy while limiting irregular bleeding and hypoestrogenic side effects.

Low-dose tyrosine kinase inhibitors reduce aberrant phosphorylation in RASopathies, improving cardiac function while avoiding overinhibition.

Small-molecule kinase modulators are tuned for blood-brain barrier penetration, high-affinity LRRK2, NUAK1, and TYK2 binding, and PET tracing.

A soft gel vaginal estradiol capsule uses medium chain oil solubilization to improve VVA treatment while minimizing discharge and side effects.

Novel dihydroquinazolinone compounds target cardiac sarcomere proteins to treat HCM while avoiding the morbidity and mortality of invasive procedures.

Sodium hyaluronate and polysorbate 80 protect loxoprofen sodium, limiting ring-opening impurities during long-term storage.

Pyridyl-amino-pyrazine compounds inhibit CHK1 kinase function, blocking DNA repair checkpoints that allow cancer cells to survive genotoxic therapy.

Macrocyclic structures optimize affinity for mutant ALK, ROS1, and TRK kinases while reducing side effects from off-target binding.

A monocyclic pyridine derivative inhibits FGFR and VEGF receptors simultaneously.

Intravaginal prasterone converts locally to active hormones, bypassing systemic exposure to treat sexual dysfunction without side effects.

Form A of Compound I monohydrochloride dihydrate manages negative symptoms and cognitive impairment while reducing extrapyramidal side effects.

siRNA conjugated to a hydrophobic albumin-binding moiety leverages endogenous albumin transport to bypass renal clearance and enhance tumor accumulation.

Carbohydrate-modified lipid nanoparticles increase luciferase expression by improving systemic delivery efficiency over conventional liposomes.

Targeting glucocorticoid and IL-27 pathways resolves the contradiction between suppressing harmful immune responses and maintaining anti-tumor immunity.

A pre-filled syringe design reduces dissolved oxygen in sugammadex solutions through solvent processing and sterile filtration steps.

Segmenting the reservoir from the diffusion barrier prevents uncontrolled drug release while maintaining consistent delivery rates.

3-disubstituted indol-2-one derivatives block ghrelin receptors to reduce food intake and body mass.

HSP70-derived peptides bind MHC class II molecules to activate regulatory T cells, reducing inflammatory responses in autoimmune diseases.

PARN inhibitors modulate miRNA stability to overcome chemotherapy resistance in cancers with reduced p53 function.

Sequential immunization with CH848 envelopes mimics viral evolution to induce broadly neutralizing antibodies.

Novel substituted piperidinylpyrazolopyrimidinones inhibit fibrinolysis to treat acute and recurrent bleeding disorders.

Tetraaza-cyclopenta[a]indenyl compounds act as positive allosteric modulators at muscarinic M1 receptors.

Ion exchange and nanofiltration purify neutral human milk oligosaccharides from fermentation broth.

A zinc salt and polyphenol composition enhances metallothionein production to regulate copper levels in therapeutic formulations.

Segmented ECM protein signatures and antibody intermediaries detect metastatic potential despite insoluble matrix complexity.

Modifying pyrazolo[1,5-a]pyrimidine structures balances inhibitor efficacy and specificity for treating proliferative diseases.

A segmented adhesive oral disc applies mucoadhesion and controlled dissolution to maintain local cannabinoid concentrations for ulcer treatment.

Iron pyrophosphate formulation with phosphatidylserine and starch enhances iron bioavailability through gastro-resistant delivery mechanisms.

Fluorinated pyrimidine analogs inhibit DNA methyltransferase, preventing deamination and extending half-life to overcome resistance in solid tumors.

Human milk oligosaccharides modulate the gut microbiome to resolve residual risk and drug intolerance in atherosclerosis treatment.

Anti-angiogenic agents inhibit kinase receptors while alpha-adrenergic agonists activate adrenergic receptors, preventing rebound hyperemia.

Specific pyrazolopyrimidine compounds resolve the contradiction between general kinase inhibition and effective Trk receptor targeting.

Nobiletin blocks the ABCB1 transporter to reverse multidrug resistance without causing systemic toxicity associated with synthetic inhibitors.

Removing the amino group from position 5 of the pyrazine moiety reduces structural complexity while maintaining potent ENaC inhibition and hydrolytic stability.

A composite bone implant uses a degradable polymer matrix to deliver antibiotics locally.

Antisense oligonucleotides recruit RNase H to degrade C9ORF72 transcripts, reducing nuclear foci and treating neurodegenerative diseases.

Removing polyaspartic acid regions from alkaline phosphatase-Fc fusion proteins prevents premature degradation and improves therapeutic efficacy.

Sulfur antioxidant prevents fentanyl degradation in adhesive layer while maintaining transdermal absorbability.

Thermo-labile oily foam collapses spontaneously at skin temperature, eliminating rubbing-induced irritation while maintaining stability for sensitive agents.

Subcutaneous Factor XII iRNA compositions inhibit gene expression to reduce bradykinin levels.

Optimizing dianhydrogalactitol dosing schedules and administration routes to enhance therapeutic efficacy in recurrent malignant glioma treatments.

Compounds stimulate astrocytic lactate release to address neglected brain energy metabolism in neurodegenerative disease treatment.

Targeted cannabinoid ratios in hemp extracts deliver therapeutic efficacy while minimizing psychoactive side effects.

Chimeric compounds bind urokinase-type plasminogen activator receptor to recruit native antibodies, reducing systemic toxicity while destroying cancer cells.

Loading carrier particles with estetrol creates an orodispersible tablet that bypasses first-pass metabolism to enhance bioavailability.

A difluoromethoxy benzamide compound stabilizes mono-ubiquitinated UBE2K to modulate microtubule assembly and inhibit tumor growth.

Sublingual nicotine stimulates endogenous alpha-MSH release to protect tissues.